ecrin-mdr-crcClinical2022IPD Sharing (as of January 2023): NoOvarian CancerTriple Negative Breast NeoplasmsGastric CancerColorectal CancerTriple Negative Breast CancerOvarian CancerTriple Negative Breast NeoplasmsGastric CancerColorectal CancerTriple Negative Breast CancerInterventionalhttps://newmdr.ecrin.org/Study/2741380United States8IrinotecanPaclitaxelNavicixizumabECRIN MDRRecruitingfalseA Study of Navicixizumab Monotherapy or in Combination in Patients With Select Advanced Solid TumorsThis is a study of navicixizumab monotherapy or in combination with paclitaxel or irinotecan in patients with advanced cancer. Patients will be enrolled into one of the following cancer cohorts: * Cohort A: CRC * Cohort B: Gastric and GEJ cancer * Cohort C: TNBC * Cohort D: Platinum-resistant/refractory epithelial ovarian, primary peritoneal, or fallopian tube cancer (ovarian cancer)2022-08-152741380NCT05453825